Learn How to Pronounce bevacizumab

Quick Answer: The International Nonproprietary Name bevacizumab is pronounced /ˌbɛvəˈsɪzjuːmæb/.
(Listen to the audio above for the stress and intonation)

The Expert's Take

Dr. Franz Lang

"I remember a student in my oncology elective last semester who was presenting a case study on metastatic colorectal cancer. She kept pronouncing this drug name with a very hard 'c', like "bevaki-zoo-mab". It was a perfect teaching moment about the soft 'c' before 'i' in many scientific terms, and we had a brief, fascinating digression on how drug names are phonetically constructed for global use. It's one of those words that looks more intimidating than it sounds."

By Dr. Franz Lang

Meaning and Context

Bevacizumab is a recombinant humanized monoclonal antibody and a cornerstone of modern targeted cancer therapy, first approved by the U.S. Food and Drug Administration (FDA) in 2004. As an anti-angiogenic agent, its primary mechanism of action involves selectively binding to vascular endothelial growth factor (VEGF), a key protein that stimulates the formation of new blood vessels (angiogenesis). By inhibiting VEGF signaling, bevacizumab effectively starves tumors of their necessary blood supply, thereby impeding their growth and metastatic potential. This groundbreaking biologic drug, commonly marketed under the brand name Avastin, is a critical component of treatment regimens for a range of malignancies, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, and certain ovarian and cervical cancers. Its integration into combination chemotherapy has significantly improved progression-free survival and overall response rates, solidifying its role as a vital weapon in the oncologist's arsenal for managing advanced-stage cancers.

Common Mistakes and Alternative Spellings

The standard and universally accepted spelling in medical literature is "bevacizumab." Common misspellings and typographical errors often arise from phonetic misinterpretation or simple slips, such as "bevacuzimab," "bevacuzumab," or "bevacimazab." Another frequent error is the omission of the second 'c', resulting in "bevazizumab." It is also sometimes incorrectly capitalized in the middle of a sentence, though it should always be written in lowercase unless starting a sentence. Users may also mistakenly refer to it by its brand name "Avastin" in contexts where the generic International Nonproprietary Name (INN) is required. The suffix "-mab" is crucial, as it identifies the drug as a monoclonal antibody, and errors like "-mib" or "-nab" are technically incorrect. Care should be taken to distinguish it from other similarly named monoclonal antibody therapies (e.g., rituximab, trastuzumab) to avoid clinical confusion.

Example Sentences

The oncologist recommended adding bevacizumab to the patient's chemotherapy regimen to target the tumor's blood supply.

After several cycles of treatment with bevacizumab, the imaging scans showed a marked reduction in the tumor's size and associated vasculature.

Due to its mechanism of inhibiting angiogenesis, a known side effect of bevacizumab is an increased risk of hypertension and impaired wound healing.

Clinical trials continue to investigate the efficacy of bevacizumab in combination with immunotherapy for various solid tumors.

The pharmacy dispensed the bevacizumab infusion, carefully following the protocol for administering biologic agents.

While highly effective, the cost of bevacizumab treatment remains a significant consideration for healthcare systems worldwide.

Sources and References

For the drug name "bevacizumab," I used the professional pharmaceutical resources on Drugs.com, which often include audio pronunciations. I also consulted its Wiktionary and Wikipedia entries. Forvo provided a clear medical pronunciation, and YouGlish offered examples from medical conferences, educational videos, and news reports.

Related Pronunciations

📂 Browse all words in the Drugs, Molecules and Vaccines category ➔